NeuroVive and Arbutus sign termination agreement


Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the
license agreement with Arbutus Biopharma (formerly OnCore Biopharma, Inc.) has
been terminated and all rights to the NVP018 compound have been reverted back to
NeuroVive. The agreement, signed in 2014, was related to the development and
commercialization of NeuroVive’s compound NVP018 for oral treatment of Hepatitis
B viral infection.
In its portfolio of several Hepatitis B compounds, Arbutus has previously made
the decision to proceed with other compounds and to discontinue the development
of NVP018 for this indication. As a consequence, the agreement between Arbutus
and NeuroVive has now been terminated.

Under the termination agreement, NeuroVive will at no cost receive NVP018 drug
product and material produced by Arbutus Biopharma, representing a value of
approximately 1.5 MUSD. Data from preclinical and CMC development have been
transferred. Furthermore, all license rights to the NVP018 compound have been
reverted to NeuroVive for further development in any potential indication.

“We have appreciated the interactions with Arbutus and there are a number of
valuable learnings that have come out of the preclinical development activities.
As we see several very exciting potential treatments with NVP018 in areas with
unmet medical need, the R&D team is currently exploring various options for
further development of these opportunities. The material provided by Arbutus
will be most useful in these activities”, said Erik Kinnman, CEO of NeuroVive.

About NVP018

NVP018 is a potent non-immunosuppressive cyclophilin inhibitor of the novel
compound class Sangamides. NVP018 is the oral version of NeuroVive’s lead
compound from its cyclophilin platform and has undergone extensive preclinical
development and evaluation in various efficacy models. The drug candidate NVP018
was licensed to a third party in September 2014, Arbutus Biopharma (formerly
OnCore Biopharma) for oral treatment of Hepatitis B.

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company
is committed to the discovery and development of medicines that preserve
mitochondrial integrity and function in areas of unmet medical need. NeuroVive
enhances the value of its projects in an organization that includes strong
international partnerships and a network of mitochondrial research institutions,
drug development and production expertise, as well as commercial partners.

NeuroVive has a project in clinical phase II development for the prevention of
moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan
drug designation in Europe and in the US. The R&D portfolio consists of several
late stage research programs in areas ranging from genetic mitochondrial
disorders to neurological and metabolic diseases.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also
traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:

Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or
ir.usa@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, at 08:30 a.m. CEST on October 21, 2016.

Attachments

10206968.pdf